AMPHASTAR PHARMACEUTICALS IN (AMPH)
US03209R1032 - Common Stock
AMPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH may be a bit undervalued, certainly considering the very reasonable score on growth This makes AMPH very considerable for value investing!
1. Profitability
1.1 Basic Checks
AMPH had positive earnings in the past year.
AMPH had a positive operating cash flow in the past year.
Each year in the past 5 years AMPH has been profitable.
AMPH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
AMPH has a Return On Assets of 9.82%. This is amongst the best in the industry. AMPH outperforms 93.26% of its industry peers.
AMPH has a better Return On Equity (23.00%) than 92.23% of its industry peers.
AMPH's Return On Invested Capital of 12.93% is amongst the best of the industry. AMPH outperforms 92.23% of its industry peers.
AMPH had an Average Return On Invested Capital over the past 3 years of 11.94%. This is significantly below the industry average of 17.70%.
The last Return On Invested Capital (12.93%) for AMPH is above the 3 year average (11.94%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.82% | ||
| ROE | 23% | ||
| ROIC | 12.93% |
ROA(3y)10.22%
ROA(5y)7.84%
ROE(3y)17.58%
ROE(5y)13.18%
ROIC(3y)11.94%
ROIC(5y)N/A
1.3 Margins
AMPH has a Profit Margin of 22.87%. This is amongst the best in the industry. AMPH outperforms 94.30% of its industry peers.
AMPH's Profit Margin has improved in the last couple of years.
AMPH has a better Operating Margin (31.29%) than 94.82% of its industry peers.
AMPH's Operating Margin has improved in the last couple of years.
AMPH's Gross Margin of 54.32% is fine compared to the rest of the industry. AMPH outperforms 63.21% of its industry peers.
In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.29% | ||
| PM (TTM) | 22.87% | ||
| GM | 54.32% |
OM growth 3Y114.39%
OM growth 5YN/A
PM growth 3Y276.41%
PM growth 5YN/A
GM growth 3Y10.26%
GM growth 5Y8.62%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
AMPH has about the same amout of shares outstanding than it did 1 year ago.
AMPH has more shares outstanding than it did 5 years ago.
AMPH has a worse debt/assets ratio than last year.
2.2 Solvency
AMPH has an Altman-Z score of 2.82. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
AMPH's Altman-Z score of 2.82 is fine compared to the rest of the industry. AMPH outperforms 74.61% of its industry peers.
AMPH has a debt to FCF ratio of 3.69. This is a good value and a sign of high solvency as AMPH would need 3.69 years to pay back of all of its debts.
AMPH has a Debt to FCF ratio of 3.69. This is amongst the best in the industry. AMPH outperforms 87.56% of its industry peers.
A Debt/Equity ratio of 0.88 indicates that AMPH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.88, AMPH is not doing good in the industry: 69.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.88 | ||
| Debt/FCF | 3.69 | ||
| Altman-Z | 2.82 |
ROIC/WACC1.52
WACC8.49%
2.3 Liquidity
A Current Ratio of 2.18 indicates that AMPH has no problem at all paying its short term obligations.
AMPH's Current ratio of 2.18 is on the low side compared to the rest of the industry. AMPH is outperformed by 63.21% of its industry peers.
A Quick Ratio of 1.72 indicates that AMPH should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.72, AMPH is not doing good in the industry: 66.32% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.18 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 75.47% over the past year.
The Earnings Per Share has been growing by 70.36% on average over the past years. This is a very strong growth
AMPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.40%.
The Revenue has been growing by 16.94% on average over the past years. This is quite good.
EPS 1Y (TTM)75.47%
EPS 3Y72.76%
EPS 5Y70.36%
EPS Q2Q%67.74%
Revenue 1Y (TTM)30.4%
Revenue growth 3Y22.59%
Revenue growth 5Y16.94%
Sales Q2Q%22.72%
3.2 Future
Based on estimates for the next years, AMPH will show a decrease in Earnings Per Share. The EPS will decrease by -4.87% on average per year.
AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.16% yearly.
EPS Next Y17.3%
EPS Next 2Y16.31%
EPS Next 3Y16.21%
EPS Next 5Y-4.87%
Revenue Next Year17.19%
Revenue Next 2Y11.5%
Revenue Next 3Y10.69%
Revenue Next 5Y1.16%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.88, the valuation of AMPH can be described as reasonable.
90.67% of the companies in the same industry are more expensive than AMPH, based on the Price/Earnings ratio.
AMPH's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.42.
A Price/Forward Earnings ratio of 9.07 indicates a reasonable valuation of AMPH.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 90.67% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.02. AMPH is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.88 | ||
| Fwd PE | 9.07 |
4.2 Price Multiples
AMPH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMPH is cheaper than 89.64% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaply inside the industry as 90.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.3 | ||
| EV/EBITDA | 8.58 |
4.3 Compensation for Growth
AMPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of AMPH may justify a higher PE ratio.
AMPH's earnings are expected to grow with 16.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.63
PEG (5Y)0.15
EPS Next 2Y16.31%
EPS Next 3Y16.21%
5. Dividend
5.1 Amount
AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (6/14/2024, 7:00:00 PM)
After market: 40.49 0 (0%)40.49
-0.14 (-0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.98B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.88 | ||
| Fwd PE | 9.07 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.63
PEG (5Y)0.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.82% | ||
| ROE | 23% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 31.29% | ||
| PM (TTM) | 22.87% | ||
| GM | 54.32% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.88 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.18 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)75.47%
EPS 3Y72.76%
EPS 5Y
EPS Q2Q%
EPS Next Y17.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)30.4%
Revenue growth 3Y22.59%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y